Friday, May 28, 2010

Prolia® (Denosumab) Granted Marketing Authorization in the European Union

Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures

First and Only Approved Treatment in Europe for Bone Loss Due to Hormone Ablation in Men with Prostate Cancer

First Prolia® Regulatory Approval

THOUSAND OAKS, Calif., May 28, 2010 /PRNewswire via COMTEX/ --Amgen Inc.  (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Prolia(R) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Prolia has been approved in all 27 European Union member states plus Norway, Iceland and Liechtenstein.  The European approval of Prolia marks the first approval of the product worldwide.

Read the rest of this entry

Posted in Press Releases

Thursday, May 20, 2010

Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting

THOUSAND OAKS, Calif., May 20, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company’s oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4- 8, 2010 in Chicago.

Read the rest of this entry

Posted in Press Releases

Friday, May 14, 2010

Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients

THOUSAND OAKS, Calif., May 14, 2010 /PRNewswire via COMTEX/ --Amgen Inc.  (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa(R) (zoledronic acid).

Read the rest of this entry

Posted in Press Releases

Wednesday, May 12, 2010

Amgen Announces Voting Results of Annual Meeting of Stockholders

THOUSAND OAKS, Calif., May 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN), today announced results of voting at the company’s Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 85 percent of outstanding shares were represented at the meeting.

Read the rest of this entry

Posted in Press Releases

Tuesday, May 11, 2010

Amgen’s Breakaway from Cancer® to Honor Cancer Survivors at Amgen Tour of California

THOUSAND OAKS, Calif. – (May 11, 2010) – Amgen today announced that four inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer® Champions to participate in Breakaway Miles during the 2010 Amgen Tour of California.

Read the rest of this entry

Posted in Press Releases